| 前收市價 | 0.6700 |
| 開市 | 0.8500 |
| 買盤 | 0.0000 |
| 賣出價 | 0.0000 |
| 拍板 | 20.00 |
| 到期日 | 2024-05-17 |
| 今日波幅 | 0.6700 - 0.8500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
ZacksSyndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
Insider MonkeySyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript February 27, 2024 Syndax Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.99. Syndax Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, everyone. […]
ZacksSyndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
